Fundraising FoxForbion — 2025 Investments
12 investments dated 2025 · listed companies and verified rows first · show all
MapLight Therapeutics is a biopharmaceutical company developing targeted treatments for central nervous system disorders through a platform designed to modulate neural circuits implicated in disease.
BiotechRedwood City, US
Anatol Kreitzer(Executive Officer)Kristopher Hanson(Executive Officer)James Lillie(Executive Officer)Jonathan Gillis(Executive Officer)inVishwas Setia(Executive Officer)inChristopher A. Kroeger(President, Chief Executive Officer and Director)
Board seatNanna Lüneborg· per SEC Form D
Co-investorsAvego BioScience CapitalPivotal Life SciencesNovo Holdings
Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.
BiotechCopenhagen, US
Garrett Winslow(Executive Officer)inLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)
Co-investorsAccess BiotechnologyViking GlobalAndreessen HorowitzBAM ElevateBay City CapitalCommodore Capital+8 more
Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases.
BiotechHealthtechMedical DevicesLondon, GB
Emma Tinsley(Founder & former CEO (now Non-Executive Director))inMai-Britt Zocca(CEO)in
Co-investorsMonograph Capital PartnersSofinnova Partners
Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment.
BiotechDeep TechMedical DevicesBrisbane, US
Jordi Mata-Fink(Chief Executive Officer, Co-Founder)inRaman Talwar(Chief Technology Officer, Co-Founder)inPat Sharp(Scientific Founder)inJordi Mata-Fink, Ph.D.(Chief Executive Officer, Co-Founder)Raman Talwar, M.S.(Chief Technology Officer, Co-Founder)Pat Sharp, Ph.D.(Scientific Founder)
Co-investorsVersant VenturesAndreessen HorowitzARCH Venture PartnersFelicis VenturesGV (Google Ventures)
Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.
BiotechMedical DevicesBasel, CH
Patrick Loustau(President and Chief Executive Officer)in
Co-investorsNovartis Venture FundSanofi VenturesVersant Ventures
Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions.
BiotechDigital HealthHealthtechMedical Devices
Travis Murdoch, M.D.(Chief Executive Officer and Board Director)in
Co-investorsAndreessen HorowitzFrazier Life SciencesOrbiMed
CellCentric develops inobrodib, a small-molecule oral p300/CBP inhibitor intended to treat multiple myeloma and other cancers.
BiotechHealthtechMedical Devices
Azim Surani(Co-founder)
Co-investorsAvego BioScience CapitalFuture Planet CapitalHBM Healthcare InvestmentsHBM PartnersRA CapitalSofinnova Partners+3 more
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)inVolker Knappertz(Executive Vice President of Research & Development)inMichael Samar(Chief Financial Officer)inRob Lasser(Chief Medical Officer)in
Co-investorsBioMedPartnersJeito CapitalRoche Venture FundSofinnova PartnersEQTEQT Life Sciences+3 more
Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Diego, US
Brent J. Warner(Executive Officer, Director)inXIN JIANG(President & CEO)inHANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)
BoardTIM LOHOFF(Director)Edward Hurwitz(Director)
Co-investorsDroia VenturesNovartis Venture FundDigitalis VenturesLightspeed Venture PartnersMPM BioImpactVida Ventures+1 more
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease.
BiotechHealthtechMedical DevicesPortland, US
Robert Jacks(Executive Officer, Director)inDavid Aaron Katz(Executive Officer, Director)
BoardJonathan Root(Director)inNiall O'Donnell(Director)inZach Scheiner(Director)inKlaus Veitinger(Director)in
Co-investorsOrbiMedRA CapitalRiverVest Venture PartnersUS Venture Partners
Tenvie is a clinical-stage biopharmaceutical company developing small molecule and biologic therapeutics for neurological and peripheral diseases.
BiotechMedical Devices
Tony Estrada(President & Chief Executive Officer; co-founder)in
Co-investorsARCH Venture PartnersF-Prime CapitalBain Capital Life SciencesDigitalis VenturesMubadala Capital
Verdiva Bio is a biotechnology company focused on drug development.
BiotechHealthtech
Jane Hughes(Chief Scientific Officer)inKhurem Farooq(Founder)in
Co-investorsGeneral AtlanticOrbiMedRA Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.